Renova Therapeutics Announces Potential Expansion of Gene Therapy Platform for Heart Failure, Diabetes and Related Conditions

Renova Therapeutics, a biotechnology company, is exploring new therapeutic opportunities to expand the use of its gene therapy platform for diabetes and heart failure-related conditions. The company plans to launch a phase 2b/3 clinical trial for heart failure and a first-in-human trial for type 2 diabetes upon regulatory approval.

Renova's Ucn2 gene therapy shows potential applications for type 1 diabetes, non-alcoholic fatty liver disease (NAFLD), hypertension, and heart failure. Preclinical data demonstrated beneficial effects in treating these conditions, including significant reductions in fatty infiltration and improvements in glucose management.

The company holds exclusive licenses to key patents and aims to develop its intellectual property further while utilizing market exclusivity granted by regulatory agencies. According to Dr. David Horwitz, a member of Renova's Scientific Advisory Board, gene therapy represents a promising approach to addressing diabetes and its complications.

Renova's CEO, Dr. Vijay Mahant, expressed confidence in the expertise of their advisory board, noting its potential to advance the company's products and benefit patients worldwide.